SBFM (Sunshine Biopharma, Inc.) קצב צמיחת רווח למניה בשנה הנוכחית

Sunshine Biopharma (SBFM) minimizes capital expenditures by outsourcing production in the US and Canada. The relative annual earnings per share growth on the GURU.Markets daily price chart reflects yield dynamics, where the 87.30 mark records this metric. Controlled laboratory expenses and sufficient cash provide stability, while future price potential is driven by oncology drug patents.

The efficiency of recruiting leading oncologists at Sunshine Biopharma (SBFM) directly impacts capitalization through the intellectual potential of its developments. The eps_yy_co metric digitizes the dynamics of net income per share, comparing current results with the same period last year to identify the real profitability trend. Analyzing the annual earnings per share growth rate allows for the filtering of transaction volatility and an assessment of the business's fundamental stability.